| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
22,090,000 |
| Market
Cap: |
286.51(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.84 - $22.64 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile roGen Pharma is a biopharmaceutical company focused on developing and commercializing solutions that treat urothelial and specialty cancers. Co.'s approved product Jelmyto® (mitomycin) for pyelocalyceal solution, and its investigational candidate, UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer, respectively. In addition, Co.'s immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
12,000 |
29,564 |
33,364 |
41,023 |
| Total Sell Value |
$168,600 |
$445,409 |
$513,847 |
$580,710 |
| Total People Sold |
1 |
2 |
2 |
2 |
| Total Sell Transactions |
1 |
5 |
6 |
11 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barrett Elizabeth A. |
Chief Executive Officer |
• – – |
2019-11-21 |
4 |
B |
$28.00 |
$210,840 |
D/D |
7,530 |
16,548 |
2.74 |
- |
|
| Barrett Elizabeth A. |
Chief Executive Officer |
• – – |
2019-11-20 |
4 |
B |
$28.00 |
$209,160 |
D/D |
7,470 |
9,018 |
2.74 |
- |
|
| Pfreundschuh Peter P. |
Chief Financial Officer |
• – – |
2019-11-20 |
4 |
S |
$28.41 |
$10,057 |
D/D |
(354) |
3,439 |
|
- |
|
| Pfreundschuh Peter P. |
Chief Financial Officer |
• – – |
2019-11-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,042 |
3,793 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2019-11-19 |
4 |
B |
$28.17 |
$55,213 |
I/I |
1,960 |
7,967 |
1.99 |
- |
|
| Barrett Elizabeth A. |
Chief Executive Officer |
• – – |
2019-11-15 |
4 |
B |
$26.00 |
$40,248 |
D/D |
1,548 |
1,548 |
2.74 |
- |
|
| Mullennix Stephen |
Chief Operating Officer |
• – – |
2019-11-14 |
4 |
S |
$26.00 |
$15,806 |
D/D |
(608) |
7,683 |
|
- |
|
| Mullennix Stephen |
Chief Operating Officer |
• – – |
2019-11-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,759 |
8,291 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2019-09-04 |
4 |
S |
$33.92 |
$11,635 |
D/D |
(343) |
6,007 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2019-09-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,041 |
6,350 |
|
- |
|
| Pfreundschuh Peter P. |
Chief Financial Officer |
• – – |
2019-08-20 |
4 |
S |
$33.07 |
$46,827 |
D/D |
(1,416) |
2,751 |
|
- |
|
| Pfreundschuh Peter P. |
Chief Financial Officer |
• – – |
2019-08-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,167 |
4,167 |
|
- |
|
| Mullennix Stephen |
Chief Operating Officer |
• – – |
2019-08-15 |
4 |
S |
$31.65 |
$19,243 |
D/D |
(608) |
6,532 |
|
- |
|
| Mullennix Stephen |
Chief Operating Officer |
• – – |
2019-08-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,759 |
7,140 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2019-06-04 |
4 |
D |
$35.05 |
$12,022 |
D/D |
(343) |
5,309 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2019-06-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,042 |
5,652 |
|
- |
|
| Mullennix Stephen |
Chief Operating Officer |
• – – |
2019-05-14 |
4 |
S |
$37.98 |
$23,092 |
D/D |
(608) |
5,381 |
|
- |
|
| Mullennix Stephen |
Chief Operating Officer |
• – – |
2019-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,759 |
5,989 |
|
- |
|
| Belldegrun Arie |
Director |
– • – |
2019-03-27 |
4 |
OE |
$4.02 |
$514,560 |
D/D |
128,000 |
212,211 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2019-03-21 |
4 |
B |
$37.01 |
$10,066 |
D/D |
272 |
4,610 |
2.74 |
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2019-03-06 |
4 |
S |
$37.30 |
$74,264 |
D/D |
(1,991) |
4,338 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2019-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,042 |
6,329 |
|
- |
|
| Mullennix Stephen |
Chief Operating Officer |
• – – |
2019-02-14 |
4 |
S |
$37.30 |
$104,589 |
D/D |
(2,804) |
4,230 |
|
- |
|
| Mullennix Stephen |
Chief Operating Officer |
• – – |
2019-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,034 |
7,034 |
|
- |
|
| Cohen Fred E |
Director |
– • – |
2019-02-06 |
4 |
OE |
$16.99 |
$254,850 |
D/D |
15,000 |
15,000 |
|
- |
|
156 Records found
|
|
Page 6 of 7 |
|
|
0.10 (0.77%) 
